Clinical trial to evaluate the safety and efficacy of CCX168 in ANCA-associated vasculitis (AAV)
| ISRCTN | ISRCTN19848432 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN19848432 |
| ClinicalTrials.gov number | NCT02222155 |
| Secondary identifying numbers | CL003_168 |
- Submission date
- 06/10/2014
- Registration date
- 17/11/2014
- Last edited
- 19/04/2021
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
ANCA (Anti-Neutrophil Cytoplasmic Antibody )-associated renal vasculitis (AAV) is an autoimmune disease involving multiple organs including the kidneys. It is caused by abnormal antibodies (autoantibodies) that attack a certain type of white blood cell (neutrophils) and can cause those neutrophils to stick to and destroy the inside walls of small blood vessels in tissue and internal organs. Standard treatment for the condition includes cyclophosphamide or rituximab plus corticosteroids. However, the complement C5a receptor CCX168 has been shown to work in mice suffering from ANCA-induced glomerulonephritis and there are encouraging results from another clinical trial involving patients with AAV. Here, we want to compare the safety and performance of two different doses of CCX168 in patients with AAV. while they continue to receive the standard of care (SOC) IV cyclophosphamide treatment, and varying doses of a prednisone or prednisone placebo.
Who can participate?
Adults aged at least 18 diagnosed with AAV.
What does the study involve?
Participants are randomly allocated to one of three groups. Those in group A are given 20mg CCX168 twice a day plus their SOC treatment for 12 weeks. Those in group B are given 30mg of CCX168 twice a day plus their SOC treatment for 12 weeks. Those in group C are given a placebo twice a day plus their SOC treatment for 12 weeks. This is followed by a 12 week follow-up period assessing the success of the treatment.
What are the possible benefits and risks of participating?
CCX168 has already been tested on healthy subjects in one study and patients with AAV in another. One of the purposes of this research study is to investigate the effects of CCX168 on vasculitis (AAV) disease activity in patients. It is possible that CCX168 may have a beneficial effect. However, there is no guarantee that any individual participant will be given CCX168 rather than placebo in this study, and there is no guarantee that CCX168 will be beneficial in the treatment of their condition. The most common side effects are headache, diarrhoea, dizziness, lower abdominal pain, nausea, vomiting, and sore throat.
Where is the study run from?
Chemocentryx (USA)
When is the study starting and how long is it expected to run for?
September 2014 to September 2019
Who is funding the study?
Chemocentryx (USA)
Who is the main contact?
Ms Antonia Potarca
apotarca@chemocentryx.com
Contact information
Scientific
850 Maude Ave.
Mountain View
94043
United States of America
| apotarca@chemocentryx.com |
Study information
| Study design | Randomized double-blind placebo-controlled Phase 2 study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A randomized, double-blind, placebo-controlled, dose assessment Phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis |
| Study acronym | CLASSIC (Clinical ANCA Vasculitis Safety and Efficacy Study of Inhibitor of C5aR) |
| Study objectives | Test whether CCX168 plus standard of care treatment is safe and efficacious in patients with AAV. |
| Ethics approval(s) | Sterling IRB, Atlanta, Georgia, 26/08/2014, IRB ID#: 4839-001 |
| Health condition(s) or problem(s) studied | ANCA-associated vasculitis (AAV) |
| Intervention | CCX168 (10 or 30 mg) twice daily plus standard of care (cyclophosphamide/rituximab plus corticosteroids). Following the 84-day dosing period, there will be an 84-day follow-up period. |
| Intervention type | Other |
| Primary outcome measure | Safety and efficacy of CCX168 in subjects with AAV on SOC cyclophosphamide or rituximab plus corticosteroid treatment. Efficacy is evaluated based on the Birmingham Vasculitis Activity Score (BVAS). BVAS assessments will be made on Days 1, 29, 85, 113, and 169. |
| Secondary outcome measures | 1. Efficacy of CCX168 compared to SOC based on changes in eGFR, Hematuria and Albuminuria will be assessed on Days 1, 2, 8, 15, 22, 29, 43, 57, 71, 85, 99, 113, 141, and 169. 2. Assessment of changes in renal inflammatory activity based on MCP-1:creatinine ratio and serum C-reactive protein concentrations with CCX168 compared to SOC will be completed on Days 1 (prior to dosing), 8, 15, 29, 57, 85, 113, and 169. 3. Assessment of health-related quality-of-life changes based on SF-36v2 and EQ-5D-5L with CCX168 compared to SOC will completed on Days 1, 29, 85, and 169. 4. Assessment of changes in VDI with CCX168 compared to SOC, made on Days 1, 85, and 169. 5. Assessment of changes in ANCA (anti-PR3 and anti-MPO) with CCX168 compared to SOC will be made on Days 1 (prior to dosing), 29, 85, 113, and 169. |
| Overall study start date | 01/09/2014 |
| Completion date | 30/09/2016 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 45 |
| Total final enrolment | 42 |
| Key inclusion criteria | 1. Male or female subjects 18 years and older, with new or relapsed AAV 2. Clinical diagnosis of granulomatosis with polyangiitis (Wegeners), microscopic polyangiitis or renal limited vasculitis 3. Female subjects of childbearing potential, and male subjects with partners of childbearing potential may participate in the study if adequate contraception is used 4. Positive indirect immunofluorescence (IIF) test for P-ANCA or C-ANCA, or positive ELISA test for anti-proteinase-3 (PR3) or anti-myeloperoxidase (MPO) at screening 5. Have at least one 'major' item, or at least three other items, or at least two renal items on the Birmingham Vasculitis Activity Score (BVAS) version 3 6. Estimated glomerular filtration rate (eGFR) ≥ 20 mL per minute |
| Key exclusion criteria | 1. Severe disease as determined by rapidly progressive glomerulonephritis or alveolar hemorrhage 2. Any other multi-system autoimmune disease 3. Medical history of coagulopathy or bleeding disorder 4. Received cyclophosphamide with 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil, or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1 5. Received intravenous corticosteroids, >3000 mg methylprednisolone equivalent, within 12 weeks prior to screening 6. Received an oral daily dose of a corticosteroid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to the screening visit 7. Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred; received anti-tumor necrosis factor (TNF) treatment, abatacept, alemtuzumab, intravenous immunoglobulin (IVIg), belimumab, tocilizumab, or plasma exchange within 12 weeks prior to screening 8. Symptomatic congestive heart failure requiring prescription medication, peripheral edema of cardiac origin, poorly-controlled hypertension, history of unstable angina, myocardial infarction or stroke within 6 months prior to screening 9. History or presence of any form of cancer within the 5 years prior to screening 10. Evidence of tuberculosis based on chest X rays 11. Positive HBV, HCV, or HIV viral screening test 12. Any infection requiring antibiotic treatment within 4 weeks prior to screening 13. Received a live vaccine within 4 weeks prior to screening 14. WBC count less than 4000/µL, or neutrophil count less than 2000/µL, or lymphocyte count less than 1000/µL 15. Hemoglobin less than 9 g/dL at screening 16. Evidence of hepatic disease 17. Prothrombin time (PT) or partial thromboplastin time (PTT) above the normal reference limit 18. Clinically significant abnormal ECG during screening 19. Participated in any clinical study of an investigational product within 30 days prior to screening 20. History or presence of any medical condition or disease which, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation |
| Date of first enrolment | 01/09/2014 |
| Date of final enrolment | 30/09/2016 |
Locations
Countries of recruitment
- Canada
- United States of America
Study participating centre
94043
United States of America
Sponsor information
Industry
850 Maude Ave.
Mountain View
94043
United States of America
"ROR" |
https://ror.org/04gp12571 |
|---|
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Abstract results | results presented at ACR/ARHP : | 28/09/2016 | 15/04/2019 | No | No |
| Results article | 01/11/2020 | 19/04/2021 | Yes | No |
Editorial Notes
19/04/2021: Publication reference added.
15/04/2019: Publication reference and total final enrolment added.
